CAS: 1535212-07-7; (33R,34S,35S,91R,92R,5S)-5-(Tert-Butyl)-N-((1R,2R)-2-(Difluoromethyl)-1-(((1-Methylcyclopropyl)Sulfonyl)Carbamoyl)Cyclopropyl)-34-Ethyl-14,14-Difluoro-17-Methoxy-4,7-Dioxo-2,8-Dioxa-6-Aza-1(2,3)-Quinoxalina-3(3,1)-Pyrrolidina-9(1,2)-Cyclopropanacyclotetradecaphane-35-Carboxamide
该化合物是一个复杂的有机化合物,其独特的结构特征,包括环丙烷环和多种功能组.该物质含有一个碳boxamide功能组,有助于其作为生物活性分子的潜力.二氟和甲氧代基替代成分的存在表明,其亲脂性和与生物目标的潜在互动性有所增强.此外,该化合物具有循环醚结构的特点,可能影响其一致性和稳定性.由(1R,2R)和(3S,4R)指定的立体化学特征表明,该物质表明其具体的原子空间安排可显著影响化合物的再活性和生物活动.
- 英文名称(33R,34S,35S,91R,92R,5S)-5-(Tert-Butyl)-N-((1R,2R)-2-(Difluoromethyl)-1-(((1-Methylcyclopropyl)Sulfonyl)Carbamoyl)Cyclopropyl)-34-Ethyl-14,14-Difluoro-17-Methoxy-4,7-Dioxo-2,8-Dioxa-6-Aza-1(2,3)-Quinoxalina-3(3,1)-Pyrrolidina-9(1,2)-Cyclopropanacyclotetradecaphane-35-Carboxamide
- 中文名称伏西瑞韦
- IUPAC名称(33R,34S,35S,91R,92R,5S)-5-(tert-butyl)-N-((1R,2R)-2-(difluoromethyl)-1-(((1-methylcyclopropyl)sulfonyl)carbamoyl)cyclopropyl)-34-ethyl-14,14-difluoro-17-methoxy-4,7-dioxo-2,8-dioxa-6-aza-1(2,3)-quinoxalina-3(3,1)-pyrrolidina-9(1,2)-cyclopropanacyclotetradecaphane-35-carboxamide
- 其它别名Voxilaprevir; Cyclopropanecarboxamide, N-[[[(1R,2R)-2-[5,5-Difluoro-5-(3-Hydroxy-6-Methoxy-2-Quinoxalinyl)Pentyl]Cyclopropyl]Oxy]Carbonyl]-3-Methyl-L-Valyl-(3S,4R)-3-Ethyl-4-Hydroxy-L-Prolyl-1-Amino-2-(Difluoromethyl)-N-[(1-Methylcyclopropyl)Sulfonyl]-, Cyclic (1→2)-Ether, (1R,2R)-; Voxilaprevir, 10 Mm In Dmso; (33R,34S,35S,91R,92R,5S)-5-(Tert-Butyl)-N-((1R,2R)-2-(Difluoromethyl)-1-(((1-Methylcyclopropyl)Sulfonyl)Carbamoyl)Cyclopropyl)-34-Ethyl-14,14-Difluoro-17-Methoxy-4,7-Dioxo-2,8-Dioxa-6-Aza-1(2,3)-Quinoxalina-3(3,1)-Pyrrolidina-9(1,2)-Cyclopropanacyclotetradecaphane-35-Carboxamide
- CAS编号1535212-07-7
- MFCD编号:MFCD32174311
- FDA UNII编号:0570F37359
- 分子式:C40H52F4N6O9S
- 分子量:868.95
- 产品CID: 754096
- 产品分类Inhibitors/Agonists → Anti-infection → HCV
物理性质
MSDS等安全信息
合成工艺路线路线简述
- 合成目标产物 Gs9857 主要起始原料 (33R,34S,35S,91R,92R,5S,E)-5-(Tert-Butyl)-34-Ethyl-14,14-Difluoro-17-Methoxy-4,7-Dioxo-2,8-Dioxa-6-Aza-1(2,3)-Quinoxalina-3(3,1)-Pyrrolidina-9(1,2)-Cyclopropanacyclotetradecaphane-35-Carboxylic Acid And (1R,2R)-1-Amino-2-(Difluoromethyl)-N-(1-Methylcyclopropylsulfonyl)Cyclopropanecarboxamide Hydrochloride
- (文献来源)合成步骤主要原料 (33R,34S,35S,91R,92R,5S,E)-5-(Tert-Butyl)-34-Ethyl-14,14-Difluoro-17-Methoxy-4,7-Dioxo-2,8-Dioxa-6-Aza-1(2,3)-Quinoxalina-3(3,1)-Pyrrolidina-9(1,2)-Cyclopropanacyclotetradecaphane-35-Carboxylic Acid 和 (1R,2R)-1-Amino-2-(Difluoromethyl)-N-(1-Methylcyclopropylsulfonyl)Cyclopropanecarboxamide Hydrochloride
海关参考信息
- 2905122000-异丙醇
2912110000-甲醛
2912120000-乙醛
2915110000-甲酸 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-9440991-B2
优先权日:2013-12-23
标 题:Synthesis of an antiviral compound
发明人：CAGULADA AMY; CHAN JOHANN; CHAN LINA; COLBY DENISE A; KARKI KAPIL KUMAR; KATO DARRYL; KEATON KATIE ANN; KONDAPALLY SUDHA; LEVINS CHRIS; LITTKE ADAM; MARTINEZ RUBEN; PCION DOMINIKA; REYNOLDS TROY; ROSS BRUCE; SANGI MICHAEL; SCHRIER ADAM J; SENG PAMELA; SIEGEL DUSTIN; SHAPIRO NATHAN; TANG DONALD; TAYLOR JAMES G; TRIPP JONATHAN; WALTMAN ANDREW W; YU LAWRENCE
权利人:GILEAD SCIENCES INC
摘要:The present disclosure provides processes for the preparation of a compound of formula I: n nwhich is useful as an antiviral agent. The disclosure also provides compounds and processes for the preparation of the compounds that are synthetic intermediates to the compound of formula I.
专利号:US-2017210756-A1
优先权日:2013-12-23
标题 :Synthesis of an antiviral compound
专利号:EP-3087085-B1
优先权日:2013-12-23
标题 :Synthesis of a macrocyclic hcv ns3 inhibiting tripeptide
专利号:KR-102366697-B1
优先权日:2013-12-23
标 题 :Synthesis of a macrocyclic hcv ns3 inhibiting tripeptide
专利号:CN-105849118-A
优先权日:2013-12-23
标 题 :Macrocyclic HCV NS3 inhibits the synthesis of tripeptides
专利号:US-10030033-B2
优先权日:2013-12-23
标 题 :Synthesis of an antiviral compound
网址: http://www.rochipharma.com
企业联系电话：021-38751876👤
地址:上海市浦东新区郭守敬路199号上海中医药创新园2楼201室
企业联系电话：021-38751876👤
📞上海润栖医药科技有限公司 ⚠️参考联系方式
联系人：余义波
电话：021-38751876
手机：15000076078
传真：021-50275764
邮箱：info@rochipharma.com
通信地址: 上海市浦东新区郭守敬路199号上海中医药创新园2楼201室
邮编: 201203
电话：021-38751876
手机：15000076078
传真：021-50275764
邮箱：info@rochipharma.com
通信地址: 上海市浦东新区郭守敬路199号上海中医药创新园2楼201室
邮编: 201203
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领，请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实，百琢研不参与任何交易。企业认领注册入口→
地址:上海市浦东新区郭守敬路199号上海中医药创新园2楼201室
⚠️ 未注册 · 未认证企业
备注: 📌 数据来源说明：本展台内容基于各搜索引擎等公开数据整理，仅作展示用途。请用户自行辨别✉️ 若企业需抹除展台内容或有异议， 请通过页面底部联系方式告知我们，我们会尽快处理。
第 1 / 1 页
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Santander Ballestín S, Gómez Martín D, Lorente Pérez S, Luesma Bartolomé MJ. Hepatitis C: A Pharmacological Therapeutic Update. J Clin Med. 2021 Apr 8;10(8):1568. doi: 10.3390/jcm10081568.
2: Garcia-Cehic D, Rando A, Rodriguez-Frias F, Gregori J, Costa JG, Carrión JA, Macenlle R, Pamplona J, Castro-Iglesias A, Cañizares A, Tabernero D, Campos C, Buti M, Esteban JI, Quer J. Resistance-associated substitutions after sofosbuvir/velpatasvir/voxilaprevir triple therapy failure. J Viral Hepat. 2021 Mar 15. doi: 10.1111/jvh.13497. Epub ahead of print. 16(2):e0245767. doi: 10.1371/journal.pone.0245767.
6: Gao LH, Nie QH, Zhao XT. Drug-Drug Interactions of Newly Approved Direct- Acting Antiviral Agents in Patients with Hepatitis C. Int J Gen Med. 2021 Jan 28;14:289-301. doi: 10.2147/IJGM.S283910.
合成参考文献
摘要:Peyrical, L. C.; Charette, A. B., Science of Synthesis: Modern Strategies in Organofluorine Chemistry , (2024) 1, 1.
参考文献:10.1007/s15006-018-0247-0|10.1007/s15006-018-0487-z
摘要:Einecke D. Title Not Available. MMW Fortschr Med. 2018 May;160(8):56. doi: 10.1007/s15006-018-0487-z.
📝 需求与反馈
尽可能描述清楚需求与问题信息
